ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis TB Drugs Go To Nonprofit

by Michael McCoy
August 25, 2014 | APPEARED IN VOLUME 92, ISSUE 34

Novartis has licensed the tuberculosis-fighting drugs in its portfolio to the nonprofit Global Alliance for TB Drug Development. The drugs, discovered at the Novartis Institutes for Tropical Diseases, include a class of compounds called indolcarboxamides. One of these compounds, NITD304, has been shown to block MmpL3, a protein essential to the TB bacterium’s survival. The agreement calls for the TB Alliance to fully take over Novartis’s TB R&D program, including financial responsibility for approval and distribution of compounds.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment